Major R&D Pipeline: 3ADCs

Other Alpha update Oncology DS-1594 (Menin-MLL binding inhibitor) AML/ALL Ph1 initiation in US (April) Pexidartinib (CSF-1/KIT/FLT3 inhibitor) Tenosynovial giant cell tumor Ph2 initiation in JP (April) Specialty Medicine DS-6016 (anti-ALK2 antibody) Fibrodysplasia ossificans progressiva Ph1 initiation in JP (April) TarligeⓇ (a28 ligand) Daiichi-Sankyo Central neuropathic pain, JP submission (May) VN-0200 (Vaccine) RS virus, Ph1 initiation in JP (June) DS-2319 (Nafamostat inhalation) COVID-19, development discontinued (June) DS-2741 (anti-Orai1 antibody) atopic dermatitis, development discontinued (June) 27

View entire presentation